A novel combination resulted in tumor regression during preclinical lab testing by scientists at the nonprofit Wistar ...

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, with a survival rate of just 11%. A primary culprit ...

A new review was published in Oncotarget's Volume 15 on November 22, 2024, entitled "Mesenchymal stem cells – the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists." ...

Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

Prostate cancer and other cancers characterized by “cold” tumors could become more responsive to checkpoint blockade if UBA1 is inhibited.

University of Michigan researchers identified UBA1 as a key player in immunotherapy resistance. Inhibiting UBA1 boosts T-cell ...

The study reveals IL-15's role in enhancing GPC3 CAR T cell therapy, improving tumor targeting and T cell survival in ...

Nov. 11, 2024 — Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface.

The Phase I trial of the combination therapy saw a an approximate 66% rate of near-complete remission in its cohort of breast ...

In an interview, Vincent Law, of Moffitt Cancer Center, discussed a new study that offers hope for patients with melanoma ...